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Atherogenesis requires and is highly influenced by the interaction between lipoproteins and macrophages. Most of the
focus to date has been on the ability of atherogenic lipoproteins (such as low-density lipoproteins, LDL) to promote and
of anti-atherogenic lipoproteins (such as high-density lipoproteins, HDL) to prevent the development of the cholesteryl
ester-enriched macrophage-derived foam cell. However, lipoprotein-macrophage interactions have the potential to modu-
late macrophage function in a variety of additional ways that may impact on atherosclerosis. These include modulating
cellular cholesterol and oxysterol content, providing fatty acids as ligands for PPARs, and acting as ligands for macro-
phage scavenger and Toll-like receptors. We suggest that atherogenic lipoproteins promote and anti-atherogenic lipopro-
teins inhibit atherogenesis by modulating macrophage function in a variety of ways beyond cholesteryl ester accumulation
and foam cell formation.Introduction
Plasma lipoproteins and macrophages play critical roles in the
initiation and progression of the atherosclerotic lesion. The cur-
rent paradigm of lipoprotein-macrophage interactions as they
relate to atherosclerosis is focused on macrophage “foam cell”
formation and can be summarized briefly as follows. Low-den-
sity lipoproteins (LDL) and other atherogenic apoB-containing
lipoproteins in the plasma cross the endothelial barrier and
gain access to the vascular subendothelial intima, where they
are retained and oxidized or otherwise modified. Monocytes
are recruited to the intima by inflammatory processes (in part
promoted by proinflammatory effects of oxidized LDL), where
they differentiate into macrophages and take up modified ath-
erogenic cholesteryl ester (CE)-rich lipoproteins via specific re-
ceptors (Figure 1). The internalized lipoproteins are targeted to
the lysosome, where their CEs are hydrolyzed to unesterified
(free) cholesterol (UC). Free cholesterol is delivered to the en-
doplasmic reticulum, where acyl:cholesterol acyltransferase 1
(ACAT1) converts much of it back to CE, which is stored in
cytoplasmic lipid droplets. Progressive accumulation of cyto-
plasmic lipid droplets leads to the morphologic appearance of
soap bubbles, responsible for the term “foam cells,” which are
generally defined biochemically by the percent of cellular cho-
lesterol that is esterified. Foam cells are considered the classic
cell type characterizing the early to intermediate atheroscle-
rotic lesion, occupying much of the lesion volume, and leading
to the progression of the disease. High-density lipoproteins
(HDL) or their major protein apoA-I interact with macrophages
to promote the efflux of excess cholesterol via specific trans-
porters of the ATP binding cassette (ABC) gene family (Wang
and Tall, 2003) and possibly other molecules, thus helping to
protect against the formation, or even induce regression, of
macrophage foam cells. Thus, the current concept of the role
of lipoprotein-macrophage interactions in atherogenesis is fo-
cused largely on the foam cell, and the foam cell itself as a
therapeutic target for intervention has been a popular theme of
reviews (Brewer, 2000; Li and Glass, 2002).CELL METABOLISM : APRIL 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVA variety of macrophage functions contribute to tissue main-
tenance, immune regulation, and defense against pathogens
and are potentially involved in atherogenesis. Many of these
functions involve recognition of specific extracellular lipid mo-
tifs that are present on the surface of exogenous microbes and
endogenous cells or lipoproteins. Here we focus on how the
intrinsic functions of macrophages are or might be influenced
by the interaction of lipoproteins with macrophages indepen-
dent of the classic foam cell paradigm. We will discuss three
classes of mechanisms by which lipoproteins may influence
macrophage function relevant to atherogenesis: (1) modulating
macrophage cholesterol and oxysterol content with subse-
quent functional effects; (2) providing (via lipase action) fatty
acids as ligands for macrophage peroxisome-proliferator acti-
vated receptors (PPARs); (3) acting as ligands for macrophage
scavenger and Toll-like receptors (TLRs) with subsequent sig-
naling events. Our overall theme is that both atherogenic and
anti-atherogenic lipoproteins have the potential to influence
macrophage function and thus atherosclerosis in a variety of
ways that go beyond CE accumulation and foam cell for-
mation.
Macrophage development and function and relationship
to atherogenesis
Macrophages are major cellular components of early as well
as advanced atherosclerotic lesions (Glass and Witztum, 2001).
Macrophages are generated by the differentiation of bone mar-
row-derived circulating monocytes as they enter peripheral tis-
sues. Monocyte colony-stimulating factor (M-CSF) is an impor-
tant factor for the development, chemotaxis, proliferation,
differentiation, and activation of monocytes and macrophages.
Consistent with a critical role for macrophages in atherosclero-
sis, mice deficient in M-CSF are relatively resistant to the de-
velopment of atherosclerotic lesions (Smith et al., 1995). Even
under homeostatic conditions, the majority of circulating
monocytes extravasate and take up residence in peripheral tis-
sues, where they have a relatively long life span. Mature resi-IER INC. DOI 10.1016/j.cmet.2005.03.005 223
R E V I E WFigure 1. Lipoproteins influence macrophage func-
tion by modulating cellular cholesterol concen-
tration
Cholesteryl-ester (CE) rich lipoproteins (Lp) are in-
ternalized by macrophage receptors, with hydrolysis
of the CE to unesterified cholesterol (UC). UC can
be transported to the plasma membrane or to the
endoplasmic reticulum (ER). Re-esterification of UC
to CE in the ER by acyl:cholesterol acyltransferase
1 (ACAT1) generates the lipid droplets characteristic
of the foam cell. If UC in the ER accumulates, it
can trigger the uncoupled protein response (UPR),
ultimately leading to apoptosis. UC can also be en-
zymatically converted to oxysterols (OS), which are
ligands for the liver X receptor (LXR). Upregulation
of ABCA1 and ABCG1 expression by liganded LXR
(and its partner RXR) promotes efflux of UC to
apoA-I and HDL, respectively. Ligation of LXR also
has important effects on blunting inflammatory gene
expression in the macrophage.dent macrophages respond to chemotactic agents, are phago-
cytic, mediate microbicidal activity, and express a variety of
genes relevant to atherogenesis, including matrix remodeling
enzymes and inflammatory mediators. Macrophages are acti-
vated by a wide variety of stimuli. The phenotype and function
of “activated” macrophages are heterogenous depending on
the balance of various cytokines and other factors in the local
microenvironment. Thus, the inflammatory environment can fa-
vor induction of, for example, the phagocytic activity, the mi-
crobicidal activity, and/or the antigen-presenting function(s) of
macrophages, or their differentiation into more specialized
cell types.
The raison d’étre of macrophages is at least 2-fold. Firstly,
macrophages are critical to tissue maintenance and homeosta-
sis through, for example, the clearance of apoptotic cells.
Clearance of apoptotic cells is mediated by scavenger recep-
tors that also mediate uptake of modified lipoproteins (Gough
and Gordon, 2000; Miller et al., 2003a). Secondly, macro-
phages play an essential role in the host response to extrinsic
challenges, most importantly, microbial pathogens. Interest-
ingly, oxidative modification of lipoprotein phospholipids gen-
erates antigens that mimic those present on microbes (Miller
et al., 2003a). Consistent with this dual function, macrophages
can be activated by either exogenous or endogenous mole-
cules. Accumulating evidence suggests that endogenous lipo-
proteins carry lipid molecules that have the ability to interact
with macrophage cell-surface and nuclear receptors and influ-
ence macrophage function.
Lipoprotein-derived cholesterol and macrophage function
The major consequence of lipoprotein uptake by macrophages
has been considered to be the generation of space-occupying
cytoplasmic CE lipid droplets characteristic of the foam cell,
thereby contributing to the initiation and progression of the
atherosclerotic plaque. However, in addition to promoting CE
accumulation, lipoprotein-derived cholesterol has the potential
to influence macrophage function (Figure 1). One example has
been recently worked out in elegant detail by Tabas and col-
leagues (Feng et al., 2003; Tabas, 2004). While much of the224cholesterol taken up by macrophages is re-esterified by ACAT1
to CE and stored in cytoplasmic droplets, under certain condi-
tions unesterified cholesterol can accumulate in the endoplas-
mic reticulum. This results in the induction of the unfolded pro-
tein response (UPR), a complex response that can ultimately
lead to apoptosis. The implications of this process for athero-
genesis and plaque rupture are still under investigation, but it
represents one mechanism by which lipoprotein-derived cho-
lesterol influences macrophage function independent of CE ac-
cumulation per se. In this model, esterification of lipoprotein-
derived cholesterol would be expected to be cyto-protective;
this may help to explain the seemingly paradoxical finding that
mice lacking macrophage ACAT1, whose macrophages cannot
form cytoplasmic CE droplets and therefore foam cells, de-
velop increased atherosclerosis (Fazio et al., 2001). A logical
extension of this model is that promotion of macrophage cho-
lesterol efflux by apoA-I or HDL may help unload the ER of
excess unesterified cholesterol and therefore protect macro-
phages from the UPR and apoptotic death; this intriguing hy-
pothesis has yet to be tested.
Lipoprotein-derived cholesterol may also have effects on the
macrophage inflammatory response. Somewhat counterintu-
itively, cholesterol loading of macrophages has been shown to
inhibit certain inflammatory responses. For example, treatment
of macrophages with oxLDL inhibited endotoxin-induced in-
ducible nitric oxide synthase (iNOS) activity (Dulak et al., 1999),
and cholesterol loading with acLDL decreased the inducibility
of TNF expression (Ares et al., 2002). In fact, uptake of lipopro-
tein cholesterol itself induces changes in macrophage expres-
sion of genes beyond those simply involved in cholesterol and
lipid metabolism. The liver X receptors (LXRα and LXRβ) are
expressed in macrophages and the endogenous ligands for
LXRs are oxysterols, generated intracellularly by enzymatic
modification of cholesterol (Repa and Mangelsdorf, 2002) (Fig-
ure 1). The LXRs appear, on balance, to be anti-atherogenic in
mice. In mouse models of atherosclerosis, deletion of LXRα/
LXRβ from macrophages is associated with increased athero-
sclerosis (Tangirala et al., 2002), and treatment of mice withCELL METABOLISM : APRIL 2005
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seph et al., 2002; Levin et al., 2005).
LXRs, through upregulation of ABC transporters such as
ABCA1 and ABCG1 (Wang et al., 2004; Wang and Tall, 2003;
Kennedy et al., 2005), are major regulators of cholesterol efflux
in macrophages, thus helping to protect the macrophage from
cholesterol overload and probably contributing to the athero-
protective effects of LXR agonists. Intriguingly, synthetic LXR
agonists also have anti-inflammatory effects that complement
their cholesterol efflux-promoting effects. Synthetic LXR li-
gands inhibit the expression of genes involved in the inflamma-
tory response of macrophages, such as iNOS, cyclooxygenase
2 (COX-2), and interleukin-6 (IL-6), in response to bacterial in-
fection or lipopolysaccharide (LPS) stimulation (Joseph et al.,
2003). Some data suggest that inhibition of inflammatory gene
expression by LXR ligands involves antagonism of NF-κB sig-
naling, but the precise molecular mechanism remains un-
known. Furthermore, LXR was recently shown to have an im-
portant role in innate immunity in response to Listeria infection,
at least in part through SPα/API6, a member of the scavenger
receptor cystine-rich repeat family (Joseph et al., 2004). HDL
is widely considered to be anti-inflammatory, at least with re-
gard to its effects on endothelial cells (Barter et al., 2004).
Somewhat paradoxically, by promoting macrophage choles-
terol efflux, HDL might be expected to reduce the intracellular
level of endogenous oxysterol LXR ligands, thus resulting in
less LXR-mediated repression of inflammatory gene expres-
sion and an increased macrophage inflammatory response
(Figure 1). Thus, LXR activation by lipoprotein-derived choles-
terol (through its oxysterol derivatives) has the potential to not
only activate the cholesterol efflux pathway but also to modu-
late macrophage inflammatory and innate immune responses.
The relative contributions of the cholesterol-efflux-promoting
effects and anti-inflammatory effects of LXR to its anti-athero-
genic effects are unknown. Further studies that separate these
effects with regard to atherosclerosis are needed and could
have implications for targeting LXR as a therapeutic approach
to atherosclerosis.
Lipoproteins as sources of ligands
for macrophage PPARs
The family of PPARs are lipid-sensing molecules for which en-
dogenous ligands are fatty acids and their derivatives. All three
PPARs (α, γ, and δ) are expressed in macrophages. In mouse
models of atherosclerosis, genetic deletion of macrophage
PPARγ resulted in increased atherosclerosis (Chawla et al.,
2001), whereas genetic deletion of PPARα (Tordjman et al.,
2001) and macrophage PPARδ (Lee et al., 2003) resulted in
reduced atherosclerosis. Synthetic PPARα agonists reduce
atherosclerosis in mice (Duez et al., 2002; Li et al., 2004). Syn-
thetic PPARγ agonists have also been shown to significantly
reduce atherosclerosis in mice (Li et al., 2000; Li et al., 2004).
In contrast, a synthetic PPARδ agonist had no effect on athero-
sclerosis in mice (Li et al., 2004). Treatment of macrophages
with synthetic ligands to PPARα, PPARγ, and PPARδ have been
reported to result in promotion of cholesterol efflux pathways
in vitro (Chawla et al., 2001; Chinetti et al., 2001; Oliver et al.,
2001). In an assessment of the effects of synthetic PPAR ago-
nists on foam cell formation in vivo, a PPARα agonist and a
PPARγ agonist inhibited foam cell formation, whereas a PPARδ
agonist did not (Li et al., 2004). Treatment of macrophages withCELL METABOLISM : APRIL 2005synthetic ligands to PPARα and PPARγ have also been shown
to inhibit inflammatory gene expression in vitro (Lee et al.,
2003; Ricote et al., 1998; Welch et al., 2003). The role of PPARδ
in macrophage inflammatory responses is complex, in that in
the absence of ligand, PPARδ actually promotes the macro-
phage-inflammatory response, possibly because the unli-
ganded PPARδ sequesters a transcriptional repressor such as
BCL-6 (Lee et al., 2003; Plutzky, 2003). Thus, the roles of the
PPARs in macrophage function and atherogenesis are com-
plex, and much of our information about their roles is derived
from studies with synthetic agonists. The nature and source of
endogenous ligands for macrophage PPARs are a relevant
topic of active interest.
Lipoproteins contain a large amount of esterified fatty acids
in the form of triglycerides and phospholipids and are therefore
potential sources of endogenous PPAR ligands. Extracellular
lipases secreted by macrophages and anchored to or near the
cell surface through binding to heparin sulfate proteoglycans
can hydrolyze lipoprotein triglycerides and phospholipids, thus
releasing fatty acids for uptake by the macrophage (Figure 2).
Macrophages express a variety of secreted lipases that have
the ability to act on lipoproteins, including lipoprotein lipase
(LPL), hepatic lipase (HL), endothelial lipase (EL) (Jin et al.,
2002), and several members of the secretory phospholipase
A2 (sPLA2) family, such as sPLA2-IIA, sPLA2-V, and sPLA2-X
(Murakami and Kudo, 2003). Macrophage expression of many
of these lipases has been shown to influence atherogenesis in
mouse models. Macrophage-specific LPL (Clee et al., 2000),
HL (Nong et al., 2003), and sPLA2-IIA (Webb et al., 2003) ex-
pression all promote atherosclerosis in mice; the EL knockout
mouse has reduced atherosclerosis, though this is not macro-
phage specific (Ishida et al., 2004). Importantly, these lipases
have different preferences for different types of lipoproteins
and lipids; for example, LPL preferentially hydrolyzes triglycer-
ides in TG-rich lipoproteins such as very low-density lipopro-
teins (VLDL), whereas EL preferentially hydrolyzes phospholip-
ids in HDL (McCoy et al., 2002). Some data indicate that
products of these lipolytic reactions can influence cellular
PPAR activation. For example, exposure of endothelial cells to
LPL-treated VLDL differentially activated all three PPARs
(PPARα >> PPARδ > PPARγ), resulting in inhibition of inflamma-
tory responses in a PPARα-dependent manner (Ziouzenkova
et al., 2003). Exposure of macrophages to VLDL resulted in the
activation of PPARδ and, to a lesser extent, PPARα (but not
PPARγ), and this effect was substantially enhanced by coincu-
bation with LPL (Chawla et al., 2003).
Thus, extracellular lipolysis of lipids in lipoproteins results in
the generation of PPAR ligands that regulate gene expression
in cells, including macrophages. The potential for specificity is
substantial, given the different types of lipoproteins (VLDL,
LDL, HDL), multiple macrophage-secreted lipases (LPL, HL,
EL, sPLA2s), and the three different PPARs expressed in ma-
crophages. It is highly likely that the action of specific lipases
on specific lipoproteins results in different PPAR activation fin-
gerprints in macrophages depending on the specific inflamma-
tory milieu. An unresolved paradox is that while PPAR activa-
tion appears to be primarily anti-atherogenic in its effects
(based on studies with synthetic agonists), the effects of these
macrophage-secreted lipases that appear to generate endoge-
nous PPAR ligands are often pro-atherogenic. More studies are
needed on the functional effects of macrophage PPAR activa-225
R E V I E WFigure 2. Lipoproteins influence macrophage func-
tion by providing, via lipases, fatty acids that serve
as ligands for peroxisome-proliferator activated re-
ceptors
Certain lipoproteins are rich in triglycerides (TG) and
all lipoproteins have a surface coat of phospholipids
(PL). A variety of secreted lipases are expressed by
macrophages and are tethered to the macrophage
cell surface through binding to heparan sulfate pro-
teoglycans (HSPGs). Lipoprotein TGs are hy-
drolyzed by lipoprotein lipase (LPL) and hepatic li-
pase (HL) and lipoprotein PLs are hydrolyzed by
endothelial lipase (EL) and members of the secre-
tory phospholipase A2 (sPLA2) family. Fatty acids
(FA) generated by lipolysis of lipoprotein TGs and
PLs enter the cell and serve as ligands, directly or
after further conversion, for PPARα, PPARγ, and
PPARδ. Ligation of macrophage PPARs may result
in promotion of cholesterol efflux via ABCA1 or
other pathways. Ligation of macrophage PPARs
may also inhibit inflammatory gene expression and
influence the expression of other genes relevant to
atherogenesis.tion, particularly by endogenous ligands, and the relationship
to atherogenesis.
Lipoproteins and macrophage scavenger receptors
Macrophages take up exogenous microorganisms and endog-
enous molecules via two broad classes of receptors. The first
class recognizes and mediates the internalization of opsonized
particles and includes the Fc receptor for immunoglobulin,
complement receptors, and fibronectin receptors. The second
class directly recognizes microorganisms or their products and
includes scavenger receptors, the TLRs, and mannose recep-
tor families. Receptors of this class are considered to fit the
general category of “pattern recognition receptors” utilized by
the immune system to recognize structural motifs characteris-
tic of pathogens (Gordon, 2002).
Macrophages express a number of scavenger receptors, in-
cluding the SR-A class (SR-AI, SR-AII, and MARCO), the
SR-B class (SR-BI, CD36), SR-D (CD68, macrosialin), SR-E
(LOX-1), and SR-F (SREC) (Greaves and Gordon, 2005) (Figure
3). These receptors exhibit specificity for motifs expressed by
microbial organisms and mediate their phagocytosis, thus
playing a key role in macrophage-mediated innate immunity
(Greaves and Gordon, 2005; Miller et al., 2003a). In addition,
many members of the scavenger receptor family are capable
of binding oxidized and modified LDL to varying degrees; in
addition, some, like SR-BI and CD36, can also bind native lipo-
proteins. At least two members of this family, SR-A and CD36,
mediate the internalization of oxidized LDL by macrophages,
leading to CE accumulation and foam cell formation.
SR-A-deficient macrophages are less prone to foam cell for-
mation when treated with modified LDL in vitro, and results
from genetically modified mice suggest that macrophage SR-A
is probably pro-atherogenic. Some studies have reported that
SR-A knockout mice have reduced atherosclerosis (Babaev et
al., 2000; Sakaguchi et al., 1998; Suzuki et al., 1997), but an-
other report on a different atherosclerosis-prone genetic back-
ground suggested that they had no decrease in atherosclerosis
(de Winther et al., 1999). Importantly, macrophage-specific de-
ficiency of SR-A was reported to be associated with signifi-226cantly reduced atherosclerosis (Babaev et al., 2000). However,
macrophage overexpression of SR-A had no effect on athero-
sclerosis (Herijgers et al., 2000; Van Eck et al., 2000). Recent-
ly, it was reported that JNK2-dependent phosphorylation of
SR-A is critical for uptake of oxidized LDL and formation of
foam cells in vitro, potentially contributing to decreased athero-
sclerosis in JNK2-deficient mice (Ricci et al., 2004). Is the ap-
parent protection from atherosclerosis in SR-A-deficient or
-defective mice due solely to reduced foam cell formation?
Macrophage SR-A may have other functions, beyond uptake
of oxLDL leading to foam cell formation, that could influence
atherogenesis. For example, ligand binding to SR-A induces
focal adhesion complexes and adhesion (Post et al., 2002). The
potential for modified lipoproteins to induce signaling through
binding to SR-A is an area of great potential interest that could
impact on the role of SR-A in atherogenesis.
CD36 is another well-characterized member of the scaven-
ger receptor family that is highly expressed on lipid-laden ma-
crophages in atherosclerotic lesions (Febbraio et al., 2001).
Macrophage CD36 is involved in a variety of processes, includ-
ing phagocytosis of apoptotic cells and the binding and inter-
nalization of long-chain fatty acids, anionic phospholipids, and
oxidized lipoproteins. Like SR-A, it has the ability to bind and
internalize oxidized LDL, leading to foam cell formation. CD36
mediates the internalization of oxLDL by macrophages through
binding to a specific family of oxidized phosphatidylcholine
molecules (Podrez et al., 2002a; Podrez et al., 2002b; Podrez
et al., 2003) leading to foam cell formation, and CD36-deficient
macrophages are much less prone to foam cell formation (Feb-
braio et al., 2000; Podrez et al., 2000). Indeed, macrophages
from mice lacking both SR-A and CD36 have a reduction of
90% in their uptake of oxidized LDL compared with wild-type
macrophages (Kunjathoor et al., 2002). The importance of
macrophage CD36 in promoting the development of murine
atherosclerosis has been established. CD36-deficient mice
have significantly reduced atherosclerosis (Febbraio et al.,
2000); even mice deficient in only macrophage CD36 were
markedly protected from the development of atherosclerosis
(Febbraio et al., 2004). Reduced foam cell formation providesCELL METABOLISM : APRIL 2005
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and modified lipoproteins
(The scavenger receptor part of this figure was adapted from a figure in Gough and Gordon, 2000, Microbes and Infection 2, 305.)at least one mechanistic explanation for reduced atherosclero-
sis in mice lacking macrophage CD36. However, CD36 may
have other effects on macrophage function independent of CE
accumulation. For example, uptake of oxLDL via CD36 leads
to activation of PPARγ, mediated at least in part through its
content of oxidized lipids such as 9-HODE and 13-HODE
(Nagy et al., 1998; Tontonoz et al., 1998) and oxidized alkyl
phospholipids (Davies et al., 2001). Macrophages from CD36-
deficient patients have defective oxLDL-induced NF-κB activa-
tion and proinflammatory gene expression (Janabi et al., 2000).
Interestingly, macrophages from mice with an induced muta-
tion in CD36 are unresponsive to microbial diacylglycerides
and lipoteichoic acid, an innate immune response pathway that
signals through TLR-2 (Hoebe et al., 2005). Thus, CD36 serves
as an adaptor linking specific microbial lipids to the macro-
phage innate immune response. It is intriguing to consider that
endogenous lipoprotein-derived lipids may induce signal trans-
duction through this or a similar pathway.
SR-BI, closely related structurally to CD36, is also expressed
by macrophages. It can bind native and modified forms of LDL
but does not lead to foam cell formation (Krieger and Kozarsky,
1999). It binds native HDL and mediates bidirectional flux of
cholesterol between macrophages and HDL (Silver and Tall,
2001). SR-BI-deficient mice have dramatically increased ath-
erosclerosis (Braun et al., 2002), and even mice specifically
lacking macrophage SR-BI have increased atherosclerosisCELL METABOLISM : APRIL 2005(Van Eck et al., 2004; Zhang et al., 2003). Thus, macrophage
SR-BI expression is anti-atherogenic; although promotion of
cholesterol efflux to HDL may be one mechanism, the precise
mechanism(s) remain unknown. Binding of HDL to SR-BI on
endothelial cells induces a signal transduction cascade result-
ing in upregulation of endothelial nitric oxide synthase (eNOS)
(Mineo et al., 2003). Whether HDL (or other types of lipopro-
teins) induce signaling in a similar fashion through binding to
macrophage SR-BI is an important question that has not been
answered. The potential roles of other members of the scaven-
ger receptor superfamily (Figure 3) in atherosclerosis have not
been fully elucidated and present other opportunities for identi-
fying functions of this family relevant to atherosclerosis.
Endogenous lipids and macrophage Toll-like receptors
Members of a second class of receptors, the TLRs, provide
another important link between lipid metabolism, the innate im-
mune response, and atherosclerosis (Michelsen et al., 2004a;
Tobias and Curtiss, 2005). The TLR family is a highly conserved
mechanism of host defense that mediates phagocytosis and
signaling (Figure 3). Several TLRs (TLR-1, -2, and -4) are ex-
pressed by activated macrophages in human atherosclerotic
lesions (Edfeldt et al., 2002). Deficiency of TLR-4 (Michelsen et
al., 2004b) or its downstream adaptor molecule myeloid differ-
entiation factor 88 (MyD88) (Bjorkbacka et al., 2004; Michelsen
et al., 2004b) results in significantly reduced atherosclerosis in227
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However, macrophage-specific deficiency in TLR-4 did not in-
fluence atherosclerosis (Tobias and Curtiss, 2005). The roles of
TLR-4 and other TLRs in atherogenesis have yet to be fully elu-
cidated.
TLRs are essential to the recognition and response to stimu-
lation by microbial components, including LPS, CpG, and mi-
crobial RNA and DNA. Increasing evidence suggests that
endogenous ligands can also stimulate TLRs. For example,
TLR-4 (a major receptor for LPS) also binds endogenous prod-
ucts such as hsp60 and fragments of fibronectin (Okamura et
al., 2001), both of which accumulate in atherosclerotic lesions
and have been causally implicated in atherogenesis. Ligand re-
cognition by macrophages via TLR-4 is a potent stimulus for
the production of interleukin-12 (IL-12), which in turn induces
the production of interferon γ, forming the basis of the pro-
atherogenic type 1 inflammatory response. The inflammatory
responses induced by other ECM components, such as frag-
ments of hyaluronan, may also be mediated by TLR family
members.
Modified lipoproteins are also ligands for the TLR family. For
example, minimally modified and oxidized LDL have been
shown to induce actin polymerization and macrophage spread-
ing through binding to CD14 and activation of signaling via
TLR-4 and its accessory protein MD-2 (Miller et al., 2003b).
This indicates that modified lipoproteins contain motifs recog-
nized by innate pattern recognition receptors and therefore
have the ability to influence macrophage function (and poten-
tially atherogenesis) through signaling events independent of
CE accumulation and foam cell formation (Miller et al., 2003a).
Furthermore, expression of LXR target genes is severely com-
promised during infection of macrophages with E. coli or influ-
enza A, and these inhibitory effects on LXR can be mimicked
by selective activation of either TLR-3 or TLR-4 (Castrillo et al.,
2003). Thus, certain lipoprotein-derived TLR-3/4 ligands may
inhibit macrophage LXR activation, thus reducing their ability
to efflux excess cholesterol as well as amplifying their inflam-
matory response. Finally, as noted above, TLR-2 is a recep-
tor that mediates signaling in macrophages in response to ex-
tracellular diacylglycerides in a process that requires CD36
(Hoebe et al., 2005). Therefore, endogenous lipoprotein-
derived lipid products might modulate atherosclerosis in part
through their activation of macrophage TLR signaling pathways.
Perspectives and implications for novel therapies
for atherosclerosis
The primordial functions of macrophages in tissue homeosta-
sis and in innate and adaptive immunity clearly influence the
manner in which macrophages respond to native and modified
lipoproteins, which, like infectious agents, contain a variety of
lipids that influence macrophage function. The primary focus of
the lipoprotein-macrophage interaction has been on the genera-
tion of CE-laden foam cells through the delivery of cholesterol by
atherogenic lipoproteins and the prevention or regression of foam
cells by the removal of cholesterol by anti-atherogenic lipopro-
teins. Might it be that macrophage CE accumulation and foam
cell formation is only one of the consequences of the interac-
tion of atherogenic lipoproteins with macrophages and that this
interaction has a variety of other effects on macrophage func-
tion that promote atherogenesis? Furthermore, might the anti-
atherogenic effects of HDL go beyond preventing or reversing228macrophage CE accumulation and extend to other effects on
macrophage function that reduce atherogenesis, inflammation,
and probability of plaque rupture? The lipoprotein-macrophage
interactions that go beyond foam cell formation have important
implications for the understanding of the pathogenesis of ath-
erosclerosis and for the development of new therapeutic ap-
proaches. An approach based on preventing foam cell forma-
tion would be focused primarily on reducing the concentrations
and internalization of atherogenic lipoproteins by and promot-
ing efflux of cholesterol from macrophages. On the other hand,
a detailed molecular understanding of lipoprotein-macrophage
interactions, their functional consequences, and their relation-
ship to atherogenesis could lead to the development of novel
molecular therapies designed to block specific atherogenic ef-
fects of apoB-containing lipoproteins or promote or mimic spe-
cific anti-atherogenic effects of HDL on macrophages. Further
studies are required to understand the molecular basis of the
effects of lipoproteins on macrophage function and dissect the
“foam cell” from the “non-foam cell” effects of lipoproteins on
macrophage function with regard to atherogenesis.
References
Ares, M.P., Stollenwerk, M., Olsson, A., Kallin, B., Jovinge, S., and Nilsson,
J. (2002). Decreased inducibility of TNF expression in lipid-loaded macro-
phages. BMC Immunol. 3, 13.
Babaev, V.R., Gleaves, L.A., Carter, K.J., Suzuki, H., Kodama, T., Fazio, S.,
and Linton, M.F. (2000). Reduced atherosclerotic lesions in mice deficient
for total or macrophage-specific expression of scavenger receptor-A. Arte-
rioscler. Thromb. Vasc. Biol. 20, 2593–2599.
Barter, P.J., Nicholls, S., Rye, K.A., Anantharamaiah, G.M., Navab, M., and
Fogelman, A.M. (2004). Antiinflammatory properties of HDL. Circ. Res. 95,
764–772.
Bjorkbacka, H., Kunjathoor, V.V., Moore, K.J., Koehn, S., Ordija, C.M., Lee,
M.A., Means, T., Halmen, K., Luster, A.D., Golenbock, D.T., and Freeman,
M.W. (2004). Reduced atherosclerosis in MyD88-null mice links elevated
serum cholesterol levels to activation of innate immunity signaling path-
ways. Nat. Med. 10, 416–421.
Braun, A., Trigatti, B.L., Post, M.J., Sato, K., Simons, M., Edelberg, J.M.,
Rosenberg, R.D., Schrenzel, M., and Krieger, M. (2002). Loss of SR-BI ex-
pression leads to the early onset of occlusive atherosclerotic coronary ar-
tery disease, spontaneous myocardial infarctions, severe cardiac dysfunc-
tion, and premature death in apolipoprotein E-deficient mice. Circ. Res. 90,
270–276.
Brewer, H.B., Jr. (2000). The lipid-laden foam cell: an elusive target for thera-
peutic intervention. J. Clin. Invest. 105, 703–705.
Castrillo, A., Joseph, S.B., Vaidya, S.A., Haberland, M., Fogelman, A.M.,
Cheng, G., and Tontonoz, P. (2003). Crosstalk between LXR and toll-like
receptor signaling mediates bacterial and viral antagonism of cholesterol
metabolism. Mol. Cell 12, 805–816.
Chawla, A., Boisvert, W.A., Lee, C.H., Laffitte, B.A., Barak, Y., Joseph, S.B.,
Liao, D., Nagy, L., Edwards, P.A., Curtiss, L.K., et al. (2001). A PPAR
gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol ef-
flux and atherogenesis. Mol. Cell 7, 161–171.
Chawla, A., Lee, C.H., Barak, Y., He, W., Rosenfeld, J., Liao, D., Han, J.,
Kang, H., and Evans, R.M. (2003). PPARdelta is a very low-density lipopro-
tein sensor in macrophages. Proc. Natl. Acad. Sci. USA 100, 1268–1273.
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Torra, I.P.,
Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001). PPAR-alpha
and PPAR-gamma activators induce cholesterol removal from human mac-
rophage foam cells through stimulation of the ABCA1 pathway. Nat. Med.
7, 53–58.CELL METABOLISM : APRIL 2005
R E V I E WClee, S.M., Bissada, N., Miao, F., Miao, L., Marais, A.D., Henderson, H.E.,
Steures, P., McManus, J., McManus, B., LeBoeuf, R.C., et al. (2000). Plasma
and vessel wall lipoprotein lipase have different roles in atherosclerosis. J.
Lipid Res. 41, 521–531.
Davies, S.S., Pontsler, A.V., Marathe, G.K., Harrison, K.A., Murphy, R.C.,
Hinshaw, J.C., Prestwich, G.D., Hilaire, A.S., Prescott, S.M., Zimmerman,
G.A., and McIntyre, T.M. (2001). Oxidized alkyl phospholipids are specific,
high affinity peroxisome proliferator-activated receptor gamma ligands and
agonists. J. Biol. Chem. 276, 16015–16023.
de Winther, M.P., Gijbels, M.J., van Dijk, K.W., van Gorp, P.J., Suzuki, H.,
Kodama, T., Frants, R.R., Havekes, L.M., and Hofker, M.H. (1999). Scaven-
ger receptor deficiency leads to more complex atherosclerotic lesions in
APOE3Leiden transgenic mice. Atherosclerosis 144, 315–321.
Duez, H., Chao, Y.S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S.,
Mallat, Z., Teissier, E., Burton, C.A., Tedgui, A., et al. (2002). Reduction of
atherosclerosis by the peroxisome proliferator-activated receptor alpha ag-
onist fenofibrate in mice. J. Biol. Chem. 277, 48051–48057.
Dulak, J., Polus, M., Guevara, I., Hartwich, J., Wybranska, I., Krzesz, R.,
and Dembinska-Kiec, A. (1999). Oxidized low density lipoprotein inhibits
inducible nitric oxide synthase, GTP cyclohydrolase I and transforming
growth factor beta gene expression in rat macrophages. J. Physiol. Phar-
macol. 50, 429–441.
Edfeldt, K., Swedenborg, J., Hansson, G.K., and Yan, Z.Q. (2002). Expres-
sion of toll-like receptors in human atherosclerotic lesions: a possible path-
way for plaque activation. Circulation 105, 1158–1161.
Fazio, S., Major, A.S., Swift, L.L., Gleaves, L.A., Accad, M., Linton, M.F.,
and Farese, R.V., Jr. (2001). Increased atherosclerosis in LDL receptor-null
mice lacking ACAT1 in macrophages. J. Clin. Invest. 107, 163–171.
Febbraio, M., Podrez, E.A., Smith, J.D., Hajjar, D.P., Hazen, S.L., Hoff, H.F.,
Sharma, K., and Silverstein, R.L. (2000). Targeted disruption of the class B
scavenger receptor CD36 protects against atherosclerotic lesion develop-
ment in mice. J. Clin. Invest. 105, 1049–1056.
Febbraio, M., Hajjar, D.P., and Silverstein, R.L. (2001). CD36: a class B scav-
enger receptor involved in angiogenesis, atherosclerosis, inflammation, and
lipid metabolism. J. Clin. Invest. 108, 785–791.
Febbraio, M., Guy, E., and Silverstein, R.L. (2004). Stem cell transplantation
reveals that absence of macrophage CD36 is protective against atheroscle-
rosis. Arterioscler. Thromb. Vasc. Biol. 24, 2333–2338.
Feng, B., Yao, P.M., Li, Y., Devlin, C.M., Zhang, D., Harding, H.P., Sweeney,
M., Rong, J.X., Kuriakose, G., Fisher, E.A., et al. (2003). The endoplasmic
reticulum is the site of cholesterol-induced cytotoxicity in macrophages.
Nat. Cell Biol. 5, 781–792.
Glass, C.K., and Witztum, J.L. (2001). Atherosclerosis. The road ahead. Cell
104, 503–516.
Gordon, S. (2002). Pattern recognition receptors: doubling up for the innate
immune response. Cell 111, 927–930.
Gough, P.J., and Gordon, S. (2000). The role of scavenger receptors in the
innate immune system. Microbes Infect. 2, 305–311.
Greaves, D.R., and Gordon, S. (2005). The immune system and atherogene-
sis. Recent insights into the biology of macrophage scavenger receptors.
J. Lipid Res. 46, 11–20.
Herijgers, N., de Winther, M.P., Van Eck, M., Havekes, L.M., Hofker, M.H.,
Hoogerbrugge, P.M., and Van Berkel, T.J. (2000). Effect of human scavenger
receptor class A overexpression in bone marrow-derived cells on lipopro-
tein metabolism and atherosclerosis in low density lipoprotein receptor
knockout mice. J. Lipid Res. 41, 1402–1409.
Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., So-
vath, S., Shamel, L., Hartung, T., Zahringer, U., and Beutler, B. (2005). CD36
is a sensor of diacylglycerides. Nature 433, 523–527.
Ishida, T., Choi, S.Y., Kundu, R.K., Spin, J., Yamashita, T., Hirata, K., Kojima,
Y., Yokoyama, M., Cooper, A.D., and Quertermous, T. (2004). Endothelial
lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-defi-
cient mice. J. Biol. Chem. 279, 45085–45092.CELL METABOLISM : APRIL 2005Janabi, M., Yamashita, S., Hirano, K., Sakai, N., Hiraoka, H., Matsumoto,
K., Zhang, Z., Nozaki, S., and Matsuzawa, Y. (2000). Oxidized LDL-induced
NF-kappa B activation and subsequent expression of proinflammatory
genes are defective in monocyte-derived macrophages from CD36-defi-
cient patients. Arterioscler. Thromb. Vasc. Biol. 20, 1953–1960.
Jin, W., Marchadier, D., and Rader, D.J. (2002). Lipases and HDL metabo-
lism. Trends Endocrinol. Metab. 13, 174–178.
Joseph, S.B., Bradley, M.N., Castrillo, A., Bruhn, K.W., Mak, P.A., Pei, L.,
Hogenesch, J., O’Connell, R.M., Cheng, G., Saez, E., et al. (2004). LXR-
dependent gene expression is important for macrophage survival and the
innate immune response. Cell 119, 299–309.
Joseph, S.B., Castrillo, A., Laffitte, B.A., Mangelsdorf, D.J., and Tontonoz,
P. (2003). Reciprocal regulation of inflammation and lipid metabolism by
liver X receptors. Nat. Med. 9, 213–219.
Joseph, S.B., McKilligin, E., Pei, L., Watson, M.A., Collins, A.R., Laffitte,
B.A., Chen, M., Noh, G., Goodman, J., Hagger, G.N., et al. (2002). Synthetic
LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl.
Acad. Sci. USA 99, 7604–7609.
Kennedy, M.A., Barrera, G.C., Nakamura, K., Baldán, A., Tarr, P., Fishbein,
M.C., Frank, J., Francone, O.L., and Edwards, P.A. (2005). ABCG1 has a
critical role in mediating cholesterol efflux to HDL and preventing cellular
lipid accumulation. Cell Metab. 1, 121–131.
Krieger, M., and Kozarsky, K. (1999). Influence of the HDL receptor SR-BI
on atherosclerosis. Curr. Opin. Lipidol. 10, 491–497.
Kunjathoor, V.V., Febbraio, M., Podrez, E.A., Moore, K.J., Andersson, L.,
Koehn, S., Rhee, J.S., Silverstein, R., Hoff, H.F., and Freeman, M.W. (2002).
Scavenger receptors class A-I/II and CD36 are the principal receptors re-
sponsible for the uptake of modified low density lipoprotein leading to lipid
loading in macrophages. J. Biol. Chem. 277, 49982–49988.
Lee, C.H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W.A., Evans, R.M.,
and Curtiss, L.K. (2003). Transcriptional repression of atherogenic inflamma-
tion: modulation by PPARdelta. Science 302, 453–457.
Levin, N., Bischoff, E.D., Daige, C.L., Thomas, D., Vu, C.T., Heyman, R.A.,
Tangirala, R.K., and Schulman, I.G. (2005). Macrophage liver X receptor is
required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb.
Vasc. Biol. 25, 135–142.
Li, A.C., and Glass, C.K. (2002). The macrophage foam cell as a target for
therapeutic intervention. Nat. Med. 8, 1235–1242.
Li, A.C., Brown, K.K., Silvestre, M.J., Willson, T.M., Palinski, W., and Glass,
C.K. (2000). Peroxisome proliferator-activated receptor gamma ligands in-
hibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin.
Invest. 106, 523–531.
Li, A.C., Binder, C.J., Gutierrez, A., Brown, K.K., Plotkin, C.R., Pattison,
J.W., Valledor, A.F., Davis, R.A., Willson, T.M., Witztum, J.L., et al. (2004).
Differential inhibition of macrophage foam-cell formation and atherosclero-
sis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114,
1564–1576.
McCoy, M.G., Sun, G.S., Marchadier, D., Maugeais, C., Glick, J.M., and
Rader, D.J. (2002). Characterization of the lipolytic activity of endothelial
lipase. J. Lipid Res. 43, 921–929.
Michelsen, K.S., Doherty, T.M., Shah, P.K., and Arditi, M. (2004a). TLR sig-
naling: an emerging bridge from innate immunity to atherogenesis. J. Immu-
nol. 173, 5901–5907.
Michelsen, K.S., Wong, M.H., Shah, P.K., Zhang, W., Yano, J., Doherty, T.M.,
Akira, S., Rajavashisth, T.B., and Arditi, M. (2004b). Lack of Toll-like receptor
4 or myeloid differentiation factor 88 reduces atherosclerosis and alters
plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad.
Sci. USA 101, 10679–10684.
Miller, Y.I., Chang, M.K., Binder, C.J., Shaw, P.X., and Witztum, J.L. (2003a).
Oxidized low density lipoprotein and innate immune receptors. Curr. Opin.
Lipidol. 14, 437–445.
Miller, Y.I., Viriyakosol, S., Binder, C.J., Feramisco, J.R., Kirkland, T.N., and
Witztum, J.L. (2003b). Minimally modified LDL binds to CD14, induces mac-229
R E V I E Wrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic
cells. J. Biol. Chem. 278, 1561–1568.
Mineo, C., Yuhanna, I.S., Quon, M.J., and Shaul, P.W. (2003). High density
lipoprotein-induced endothelial nitric-oxide synthase activation is mediated
by Akt and MAP kinases. J. Biol. Chem. 278, 9142–9149.
Murakami, M., and Kudo, I. (2003). New phospholipase A(2) isozymes with
a potential role in atherosclerosis. Curr. Opin. Lipidol. 14, 431–436.
Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., and Evans, R.M. (1998).
Oxidized LDL regulates macrophage gene expression through ligand acti-
vation of PPARgamma. Cell 93, 229–240.
Nong, Z., Gonzalez-Navarro, H., Amar, M., Freeman, L., Knapper, C., Neu-
feld, E.B., Paigen, B.J., Hoyt, R.F., Fruchart-Najib, J., and Santamarina-
Fojo, S. (2003). Hepatic lipase expression in macrophages contributes to
atherosclerosis in apoE-deficient and LCAT-transgenic mice. J. Clin. Invest.
112, 367–378.
Okamura, Y., Watari, M., Jerud, E.S., Young, D.W., Ishizaka, S.T., Rose, J.,
Chow, J.C., and Strauss, J.F., 3rd. (2001). The extra domain A of fibronectin
activates Toll-like receptor 4. J. Biol. Chem. 276, 10229–10233.
Oliver, W.R., Jr., Shenk, J.L., Snaith, M.R., Russell, C.S., Plunket, K.D., Bod-
kin, N.L., Lewis, M.C., Winegar, D.A., Sznaidman, M.L., Lambert, M.H., et al.
(2001). A selective peroxisome proliferator-activated receptor delta agonist
promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98,
5306–5311.
Plutzky, J. (2003). Medicine. PPARs as therapeutic targets: reverse cardiol-
ogy? Science 302, 406–407.
Podrez, E.A., Febbraio, M., Sheibani, N., Schmitt, D., Silverstein, R.L.,
Hajjar, D.P., Cohen, P.A., Frazier, W.A., Hoff, H.F., and Hazen, S.L. (2000).
Macrophage scavenger receptor CD36 is the major receptor for LDL modi-
fied by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105,
1095–1108.
Podrez, E.A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton,
P.J., Shan, L., Febbraio, M., Hajjar, D.P., et al. (2002a). A novel family of
atherogenic oxidized phospholipids promotes macrophage foam cell for-
mation via the scavenger receptor CD36 and is enriched in atherosclerotic
lesions. J. Biol. Chem. 277, 38517–38523.
Podrez, E.A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton,
P.J., Shan, L., Gugiu, B., Fox, P.L., et al. (2002b). Identification of a novel
family of oxidized phospholipids that serve as ligands for the macrophage
scavenger receptor CD36. J. Biol. Chem. 277, 38503–38516.
Podrez, E.A., Hoppe, G., O'Neil, J., and Hoff, H.F. (2003). Phospholipids in
oxidized LDL not adducted to apoB are recognized by the CD36 scavenger
receptor. Free Radic. Biol. Med. 34, 356–364.
Post, S.R., Gass, C., Rice, S., Nikolic, D., Crump, H., and Post, G.R. (2002).
Class A scavenger receptors mediate cell adhesion via activation of G(i/o)
and formation of focal adhesion complexes. J. Lipid Res. 43, 1829–1836.
Repa, J.J., and Mangelsdorf, D.J. (2002). The liver X receptor gene team:
potential new players in atherosclerosis. Nat. Med. 8, 1243–1248.
Ricci, R., Sumara, G., Sumara, I., Rozenberg, I., Kurrer, M., Akhmedov, A.,
Hersberger, M., Eriksson, U., Eberli, F.R., Becher, B., et al. (2004). Require-
ment of JNK2 for scavenger receptor A-mediated foam cell formation in
atherogenesis. Science 306, 1558–1561.
Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. (1998). The
peroxisome proliferator-activated receptor-gamma is a negative regulator
of macrophage activation. Nature 391, 79–82.
Sakaguchi, H., Takeya, M., Suzuki, H., Hakamata, H., Kodama, T., Horiuchi,
S., Gordon, S., van der Laan, L.J., Kraal, G., Ishibashi, S., et al. (1998).
Role of macrophage scavenger receptors in diet-induced atherosclerosis in
mice. Lab. Invest. 78, 423–434.230Silver, D.L., and Tall, A.R. (2001). The cellular biology of scavenger receptor
class B type I. Curr. Opin. Lipidol. 12, 497–504.
Smith, J., Trogan, E., Ginsberg, M., Grigaux, C., Tian, J., and Miyata, M.
(1995). Decreased atherosclerosis in mice deficient in both macrophage
colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci.
USA 92, 8264–8268.
Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka, M., Jishage, K.,
Ueda, O., Sakaguchi, H., Higashi, T., Suzuki, T., et al. (1997). A role for
macrophage scavenger receptors in atherosclerosis and susceptibility to
infection. Nature 386, 292–296.
Tabas, I. (2004). Apoptosis and plaque destabilization in atherosclerosis:
the role of macrophage apoptosis induced by cholesterol. Cell Death Differ.
11, S12–S16.
Tangirala, R.K., Bischoff, E.D., Joseph, S.B., Wagner, B.L., Walczak, R., Laf-
fitte, B.A., Daige, C.L., Thomas, D., Heyman, R.A., Mangelsdorf, D.J., et
al. (2002). Identification of macrophage liver X receptors as inhibitors of
atherosclerosis. Proc. Natl. Acad. Sci. USA 99, 11896–11901.
Tobias, P., and Curtiss, L.K. (2005). Paying the price for pathogen protec-
tion: toll receptors in atherogenesis. J. Lipid Res. 46, 404–411.
Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., and Evans, R.M. (1998).
PPARgamma promotes monocyte/macrophage differentiation and uptake
of oxidized LDL. Cell 93, 241–252.
Tordjman, K., Bernal-Mizrachi, C., Zemany, L., Weng, S., Feng, C., Zhang,
F., Leone, T.C., Coleman, T., Kelly, D.P., and Semenkovich, C.F. (2001).
PPARalpha deficiency reduces insulin resistance and atherosclerosis in
apoE-null mice. J. Clin. Invest. 107, 1025–1034.
Van Eck, M., De Winther, M.P., Herijgers, N., Havekes, L.M., Hofker, M.H.,
Groot, P.H., and Van Berkel, T.J. (2000). Effect of human scavenger receptor
class A overexpression in bone marrow-derived cells on cholesterol levels
and atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol.
20, 2600–2606.
Van Eck, M., Bos, I.S., Hildebrand, R.B., Van Rij, B.T., and Van Berkel, T.J.
(2004). Dual role for scavenger receptor class B, type I on bone marrow-
derived cells in atherosclerotic lesion development. Am. J. Pathol. 165,
785–794.
Wang, N., and Tall, A.R. (2003). Regulation and mechanisms of ATP-binding
cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler.
Thromb. Vasc. Biol. 23, 1178–1184.
Wang, N., Lan, D., Chen, W., Matsuura, F., and Tall, A.R. (2004). ATP-binding
cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-
density lipoproteins. Proc. Natl. Acad. Sci. USA 101, 9774–9779.
Webb, N.R., Bostrom, M.A., Szilvassy, S.J., van der Westhuyzen, D.R.,
Daugherty, A., and de Beer, F.C. (2003). Macrophage-expressed group IIA
secretory phospholipase A2 increases atherosclerotic lesion formation in
LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 263–268.
Welch, J.S., Ricote, M., Akiyama, T.E., Gonzalez, F.J., and Glass, C.K.
(2003). PPARgamma and PPARdelta negatively regulate specific subsets of
lipopolysaccharide and IFN-gamma target genes in macrophages. Proc.
Natl. Acad. Sci. USA 100, 6712–6717.
Zhang, W., Yancey, P.G., Su, Y.R., Babaev, V.R., Zhang, Y., Fazio, S., and
Linton, M.F. (2003). Inactivation of macrophage scavenger receptor class B
type I promotes atherosclerotic lesion development in apolipoprotein
E-deficient mice. Circulation 108, 2258–2263.
Ziouzenkova, O., Perrey, S., Asatryan, L., Hwang, J., MacNaul, K.L., Moller,
D.E., Rader, D.J., Sevanian, A., Zechner, R., Hoefler, G., and Plutzky, J.
(2003). Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands:
evidence for an antiinflammatory role for lipoprotein lipase. Proc. Natl.
Acad. Sci. USA 100, 2730–2735.CELL METABOLISM : APRIL 2005
